Healthcare & Pharmaceuticals

Market-leading effective advice built on strong foundations

Healthcare and life sciences companies come to King & Wood Mallesons not just because we have the right expertise and the best people, but because we put in the work it takes to understand the sector.

Navigating healthcare legislation is rarely straightforward given scientific advances, ever-changing government regulation and strict ethical considerations.

We make sure our legal advice is based on a comprehensive knowledge of current developments in the industry. We scour legal and commercial developments in pharmaceuticals and medicine as they happen and share them with clients so that we can all stay at the cutting edge.

Navigating the pandemic and rapidly changing settings

We have helped clients navigate the challenges presented by the COVID-19 pandemic. We understand better than most this heavily regulated environment, the drivers of rapid changes across the health sector, opportunities for novel technologies and treatments, and evolving healthcare models.

Our large portfolio of health sector clients equips us with insights into issues most likely to impact you. We know how to best manage and resolve commercial and legal issues, no matter the complexity.

KWM’s health sector specialists bring first-hand experience assisting on a full range of transactions and matters, including:

Complex Patent Disputes

Major M&A Transactions

Product liability Defences

High-Stake Regulatory Investigations

Provision of Ongoing Targeted Commercial & Regulatory Advice.

We know you must move fast sometimes to get a deal done, or to respond to an issue, so we focus on making sure you get a straight answer quickly.

Our lawyers advise companies working in:

Pharmaceuticals – including originators and generics

Biotechnology

Research & Eevelopment

Medical Devices

Health Insurance

Health Services

Hospitals & Medical Facilities

Aged Care & Retirement Villages.

We also advise private equity firms, investors and financial advisers to the sector.

Insight

The regulation of psychedelic substances in the United States

A number of recent state and local legislative reforms have made some psychedelic substances accessible in the United States. For example, in 2020, Oregon became the first state to ‘decriminalise’ psilocybin and legalise it for therapeutic use. Earlier in 2019, Denver Colorado became the first city to ‘decriminalise’ the use or possession of psilocybin by people over 21.

03 July 2023

Publication

KWM’s Guide to Doing Business in Australia

In this publication we provide an outline of the key legal, social and tax considerations relevant to doing business in Australia. We share our industry experts’ knowledge and insight into issues and trends impacting sectors, including Food and Agribusiness, Energy and Resources, Infrastructure and FinTech.

06 December 2022

Insight

China relaxes rules on lab-developed tests – but uncertainties remain

New regulations in China designed to encourage innovation in clinical trials have made it easier to test human samples in a lab setting.

19 May 2022